Market Closed

SCYX
SCYNEXIS
$ 3.21
-3.60%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago

SCYNEXIS News

Latest SCYNEXIS Stock News & SCYX Headlines

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10 days ago | globenewswire.com
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
17 days ago | globenewswire.com
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
24 days ago | globenewswire.com
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
24 days ago | globenewswire.com
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
a month ago | defenseworld.net
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
a month ago | globenewswire.com
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
2 months ago | globenewswire.com
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
2 months ago | globenewswire.com
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
2 months ago | globenewswire.com
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
2 months ago | globenewswire.com
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

SCYX
SCYNEXIS
$ 3.21
-3.60%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated a day ago